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Abstract
Introduction: Ongoing prospective trials exploring stereotactic body radiation therapy (SBRT) for early stage
non-small cell lung cancer (NSCLC) often exclude minimally invasive adenocarcinoma or adenocarcnioma in situ,
formerly bronchioloalveolar carcinoma (BAC), due to concerns for accurate target delineation on CT. We performed
a patterns of failure analysis to compare outcomes between BAC and other NSCLC subtypes.
Methods: One hundred twenty patients with early stage NSCLC were treated with SBRT from 2004–2009.
Pathologic confirmation of NSCLC was obtained in 97 patients. Radiotherapy was delivered according to RTOG
guidelines. The log-rank test was used to compare outcomes between BAC and other NSCLC.
Results: Median follow-up was 29 months. The median SBRT dose was 5400 cGy. Thirteen patients had
radiographically diagnosed BAC and five patients had biopsy confirmed BAC, of which two had both. The
three-year local control was 100% for biopsy-proven or radiographically diagnosed BAC (n = 18) and 86% for all
other NSCLC subtypes (n = 102) (p = 0.13). Likewise, no significant difference was detected between BAC and other
NSCLC for 3-year regional failure (12% vs. 20%, p = 0.45), progression-free survival (57.6% vs. 53.5%, p = 0.84) or
overall survival (35% vs. 47%, p = 0.66). There was a trend towards lower three-year rates of freedom from distant
failure in patients with any diagnosis of BAC compared to those without (26% vs. 38%, p = 0.053).
Conclusions: Compared to other NSCLC subtypes, BAC appears to have similar patterns of failure and survival after
treatment with SBRT, however there may be an increased risk of distant metastases with BAC. RTOG
guideline-based target delineation provides encouraging local control rates for patients with BAC.
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Introduction
Stereotactic Body Radiotherapy (SBRT) has become a
standard of care treatment for medically inoperable
patients with early stage non-small cell lung cancer
(NSCLC) [1]. Multiple prospective clinical trials have
established the safety and efficacy of SBRT for the treat-
ment of early stage NSCLC [2-9]. Fakiris et al. reported
three year local control and cause specific survival rates
of 88% and 82% respectively, and grade 3–4 toxicity
rates of 10% for peripheral lung tumors [2]. RTOG 0236
reported similar findings for patients with peripheral
tumors with three-year local control and disease free
survival rates of 91% and 48% respectively, and grade 3–4
toxicity rates of 17% [3].
Bronchioloalveolar carcinoma (BAC), recently renamed
as adenocarcinoma in situ or minimally invasive adenocar-
cinoma [10], is a sub-type of NSCLC with unique imaging
characteristics and natural history relative to other sub-
types. While invasive subtypes of BAC follow typical
routes of lymphatic spread to hilar and mediastinal lymph
nodes and metastasize outside of the thorax, non-invasive
BAC frequently demonstrates a lepidic pattern of spread
along alveoli, disseminating widely throughout the lung
parenchyma [11]. In the United States, estimates of the in-
cidence of BAC have varied from as high as 24 percent in
a single institution series to less than 5 percent in a large
series based upon the Surveillance, Epidemiology and End
Results (SEER) database [12,13]. Pathologic confirmation
of BAC is frequently unavailable for patients undergoing
SBRT due to their inability to tolerate a needle biopsy be-
cause of medical comorbidities. In one single institution
study of SBRT for medically inoperable lung cancer
patients 29% of patients are treated without histologic
confirmation [6]. In patients that do undergo biopsy,
pathologists may not diagnose BAC unless the entire spe-
cimen is available. The inability to obtain histologic con-
firmation of BAC on a large percentage of patients
undergoing SBRT has led to a frequent reliance on radio-
graphic diagnosis of BAC.
Computed Tomography (CT) of the chest is the stand-
ard imaging test for the diagnosis of BAC. The variation
in the patterns of tumor growth for BAC can lead to a
variety of radiologic findings. In 40% of patients diag-
nosed with BAC, the tumor presents on CT imaging as
solitary pulmonary nodules or masses [14]. The CT
appearance of these lesions is a continuous spectrum be-
tween well-defined nodules and ground glass opacities
(GGO) [15]. The GGO component of the tumor corre-
lates with the lepidic growth pattern of the malignancy
[16]. Lesions with both solid and GGO components sug-
gest a mixed subtype of adenocarcinoma such as BAC
with focal invasion and adenocarcinoma with BAC fea-
tures [17]. An increasing size of the solid component
correlates with a higher risk of an invasive component
[14]. Lesions with GGO components on CT present a
target delineation issue when treating early stage BAC
with SBRT. There is currently no published literature on
the appropriate way to design clinical target volumes for
patients with BAC.
The utility of FDG-PET scanning in the diagnosis of
BAC has recently been explored by multiple institutions.
The sensitivity and specificity of FDG-PET in the diag-
nosis of BAC varies greatly depending on the presence
of an invasive carcinoma component in the BAC. FDG-
PET has been shown to miss up to 67% of BAC tumors
without invasive components [18]. However, in cases of
adenocarcinoma with BAC features, the diagnostic per-
formance of FDG-PET was similar to other NSCLC [18].
The typical standardized uptake values (SUVs) of BAC
are less than more virulent forms of NSCLC. This is
likely due to BAC’s longer doubling time [19,20]. The
median SUV of BAC lesions has been reported to be 2.5
which is also the typical threshold value for differentiat-
ing between and benign and malignant lesions [17]. BAC
lesions with high SUV are more likely to have an inva-
sive component and have a worse prognosis [21]. How-
ever, the typically low SUV of BAC lesions limits the
usefulness of FDG-PET scanning in the diagnosis of
BAC by resulting in a high false-negative rate [22].
In light of a perceived difficulty in target delineation
on CT due to a propensity for a lepidic pattern of
growth, ongoing prospective trials exploring SBRT for
early stage NSCLC (RTOG 0618, RTOG 0915) have
excluded BAC [23,24]. As such, reported outcomes from
these studies cannot be used to infer utility of SBRT for
BAC. Likewise, no other specific comparison in out-
comes or patterns of failure has been made between
BAC and other NSCLC histologies treated with SBRT to
date. Therefore, we performed a comprehensive patterns
of failure analysis to compare outcomes between BAC
and other NSCLC subtypes.
Materials and methods
An Institutional Review Board (IRB) - approved registry
of patients undergoing lung SBRT from 2004–2009 at
the Mallinckrodt Institute of Radiology was used for se-
lection of 120 patients who were (1) treated with defini-
tive intent for early stage disease, and (2) without history
of malignancy in the preceding 2 years. Pathologic con-
firmation of NSCLC was obtained in 97 patients via CT
guided biopsy or bronchoscopy. The remaining 23
patients did not undergo a biopsy attempt due to high
clinical concern for pneumothorax. All patients under-
went a chest CT scan, and the metastatic workup also
included an abdominal CT scan (n = 45) and/or a [18 F]
fluorodeoxyglucose (FDG) positron emission tomog-
raphy (PET) scan (n = 112) for all patients. The CT stud-
ies of the chest were reviewed by a fellowship trained
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board certified thoracic radiologist (AJB). Diagnosis of
BAC was based on imaging characteristics typical of
BAC, such as ground glass nodule, solid nodule with
ground glass halo, consolidation with air bronchograms,
and nodules with pseudocavitation [25]. These imaging
characteristics would correspond to adenocarcinoma in
situ (AIS) and minimally invasive adenocarcinoma
(MIA) (although there is overlap of the imaging features)
[26]. BAC (currently AIS) was radiographically diag-
nosed if the nodule was purely ground glass. BAC (cur-
rently MIA) was also radiographically diagnosed if there
was a ground glass nodule with a solid component or a
nodule was present with pseudocavitation. Nodules that
were completely solid, spiculated, and nodules with a
CT angiogram sign were not given a diagnosis of BAC
based on CT imaging characteristics.
The simulation and treatment planning procedures at
our institution have been previously described [7]. Briefly,
all patients underwent four-dimensional CT (4D-CT) with-
out intravenous contrast using a 16 slice CT (Somatom
Sensation 16, Philips Medical, Cleveland, OH) to determine
tumor motion for target delineation. Patients were immobi-
lized using either the Elekta Stereotactic Body Frame (SBF)
(Elekta, Crawley, England) (n = 83), the BodyFIXW system
(Medical Intelligence, Munich, Germany) (n = 28), or an
Alpha Cradle (Smithers Medical Products, North Canton,
OH) (n = 7). Two morbidly obese patients were immobi-
lized using the VacLoc bag component of the BodyFIXW
system alone. For patients immobilized with the SBF, an ini-
tial limited-field 4DCT was used to determine the longitu-
dinal extent of tumor excursion during quiet respiration,
and additional immobilization using diaphragmatic com-
pression was applied for 30 patients (33%) with tumor
excursions greater than 5 mm in the craniocaudal
direction.
After co-registration of the 4D-CT to the simulation
CT an internal target volume (ITV) was created to en-
compass the maximum intensity projection (MIP), and
an additional PTV expansion was made following RTOG
guidelines [27]. No additional measures were taken with
regard to target delineation for suspected or proven
BAC, nor were any modifications to the planning target
Figure 1 Target volumes for a representative patient with BAC treated with SBRT. Using a 4D CT simulation an ITV is created. A 0.5 cm
margin is added to the ITV to create a PTV.
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volume (PTV) made other than those defined above
(Figure 1). Prior to each treatment, tumors were loca-
lized using cone-beam CT image guidance and fluoros-
copy was used confirm that the tumor was encompassed
by the PTV when anatomically feasible.
Follow-up was performed with regular CTs of the
chest without intravenous contrast according to institu-
tional guidelines previously described [7]. Local control
was defined as an absence of primary tumor progression
(i.e., any response or stable disease) and absence of
involved-lobe recurrence. FDG-PET/CT imaging was
used in cases of suspected tumor relapse to aid differen-
tiation between local recurrence and fibrosis. Nodal
failures were defined as hilar or mediastinal nodal en-
largement on CT with FDG-PET positivity, and distant
failures were defined as any failure outside the thorax.
The survival and patterns of lung cancer failure in the
patients with BAC was compared to all other patients
with NSCLC treated with SBRT. The log-rank test was
used to compare local control (LC), hilar failure, medias-
tinal failure, regional failure, freedom from distant failure
(FFDF), progression free survival (PFS), and overall sur-
vival (OS), and was used for reported p values. Statistical
analyses were performed using SASW version 9.2.
Results
One-hundred twenty patients that met study criteria
were treated with SBRT between July 2004 and May
2009. Median follow-up was 29 months for all patients
and 39 months for living patients. Median age was
74 years (range, 31–92), and 58 (48%) patients were
female. Median SBRT dose was 5400 cGy in 3 fractions,
and ranged from 4500 cGy to 6956 cGy in 3–6 fractions.
Ninety-three patients (78%) were treated to 5400 cGy in
3 fractions and 11 patients (9%) received 5000 cGy in 5
fractions. The breakdown of NSCLC subtypes for 97
patients with pathologic confirmation of disease is
shown in Table 1.
Fifteen patients were deemed to have BAC based on
pre-treatment chest CT. Of the 15 patients with radio-
logical diagnosis of BAC, 3/15 did not have a biopsy, 6/15
had biopsy proven adenocarcinoma, 4/15 had biopsy
proven NSCLC not otherwise specified, and 2/15 had bi-
opsy proven BAC or adenocarcinoma with BAC features.
Twelve of the fifteen patients with radiological diagnosis
of BAC had GGOs. Two patients had a radiographical
diagnosis of BAC but had a pathological diagnosis of squa-
mous cell carcinoma, and thus were not included in the
analysis. By combining patients with either a histologic
(n = 5) or radiographic (n = 13) diagnosis of BAC a sub-
group of eighteen patients with BAC was created for
comparison with the entire study population.
Table 1 Summary of radiologic and histologic diagnoses
for patients with BAC and non-BAC NSCLC








Figure 2 No significant difference was detected between BAC
and non-BAC NSCLC for three-year (A) Overall Survival (35% vs
47%, p = 0.66) and (B) Progression Free Survival (53% vs 48%,
p = 0.96).
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There was no difference in three-year overall survival
(OS) (35% vs 47%, p = 0.66) or three-year progression-
free survival (PFS) (53% vs 48%, p = 0.96) between
patients with any (radiologic or histologic) diagnosis of
BAC and those without (Figure 2). Similarly, no differ-
ence was seen in three-year rates of local control
(defined as lack of tumor recurrence within the treated
area) (100% vs 86%, p = 0.13), or regional (hilar or medi-
astinal) nodal control (88% vs 80%, p = 0.45) between
patients with any diagnosis of BAC and those without
(Figures 3A, 3B).
There was a trend toward lower three-year rates of
distant control in patients with any diagnosis of BAC
compared to those without (26% vs. 38%, p = 0.053)
(Figure 3C). Nine of eighteen patients with any diagnosis
of BAC developed metastases. Of those nine, four devel-
oped pulmonary metastases, four developed extrapulmon-
ary metastases and one developed both. No significant
difference was seen in three-year rates of pulmonary me-
tastases (34% vs 17%, p = 0.17) or three-year rates of extra-
pulmonary metastases (21% vs. 18%, p = 0.23) between
patients with any diagnosis of BAC and those without.
Discussion
The patterns of failure of early stage NSCLC after SBRT
have been reported by multiple institutions, however no
institution to date has specifically reported the patterns
of failure after SBRT for BAC [2,3,5,6,8,9]. Ongoing pro-
spective trials exploring SBRT for early stage NSCLC
(RTOG 0618, RTOG 0915) have excluded BAC [23,24].
Thus, reported outcomes from these studies cannot be
used to infer utility of SBRT for BAC.
A large SEER analysis found that patients with bronch-
ioloalveolar carcinoma that underwent lobectomy had
improved overall survival compared to those that under-
went wedge resection or segmentectomy [28]. However,
prospective studies have found that wedge resection is
potentially curative for patients with non-invasive BAC
[29-31].
The pattern of failure after surgical removal of BAC
was evaluated in a series of 93 patients with Stage I-IV
histologically confirmed BAC that underwent wedge re-
section, lobectomy or pneumonectomy for their disease.
Any lung recurrence was reported in 39 (42%) patients.
Thirteen (33%) of the recurrences were multiple lung
nodules, eight (21%) as a single nodule or mass, four as
an infiltrating or pneumonic mass, four as miliary
lesions, four as mixed alveolar and nodular opacity, four
Figure 3 No significant difference was detected between BAC
and non-BAC NSCLC for three-year (A) Local Control (100% vs
86%, p = 0.13) (B) Regional Control (88% vs 80%, p = 0.45). There
is a trend toward lower three-year rates of distant control (26% vs 38%,
p = 0.053) in patients with BAC vs non-BAC NSCLC (C).
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as lymphangitic spreading, and one each as a pleural ef-
fusion or rib destruction [32].
It is estimated that the risk of developing a second
lung cancer in patients who survived resection of a non-
small-cell lung cancer is approximately 1%-2% per
patient per year [33]. Unless the patient’s second lung
cancer is histologically unique it is difficult to ascertain
whether the second lung cancer is a metastasis of the
first cancer or a de novo cancer. This issue caused uncer-
tainty in coding the patterns of failure after SBRT in our
study. We elected to code multiple synchronous recur-
rences in the lung outside of the field of treatment as
pulmonary metastases and a single new mass/nodule
outside of the field of treatment as a second lung cancer.
We found that there is a trend towards an increased
rate of metastases after SBRT in patient with a radiologic
or histologic diagnosis of BAC compared to those with a
diagnosis of non-BAC NSCLC (Figure 3C). This finding
may be confounded by the known propensity for BAC to
spread diffusely throughout the lungs. When considering
only pulmonary metastases, there was no significant dif-
ference between patients with BAC compared to those
with non-BAC NSCLC, but the results were limited by a
smaller sample size.
As described above, patients with BAC were treated in
an identical fashion as other patients with early stage
NSCLC (Figure 1). We had no local failures amongst
patients with BAC, and 12% rate of local failure (n = 12)
in patients with non-BAC NSCLC which is consistent
with the rates of local failure seen in SBRT series from
other institutions [2-6,8,9]. There is a concern for mar-
ginal recurrence of BAC after less extensive local therapy
such as a wedge resection instead of standard of care
lobectomy. As mentioned previously a number of surgi-
cal series have found excellent local control rates after
wedge resection for non-invasive BAC [29-31]. However,
the local control rates after wedge resection for invasive
Stage I NSCLC including those with a BAC component
are not as favorable. A randomized trial of lobectomy
versus a limited resection (wedge or segmentectomy) for
T1 N0 NSCLC found increased rates of locoregional re-
currence (17% vs 6%) and any recurrence (34% vs 26%)
in patients who received a limited resection compared to
those receiving lobectomy. These higher rates of recur-
rence led to a 50% increased rate of death with cancer
and a 30% increase in overall death rate [34].
SBRT for localized BAC provides excellent local con-
trol and has similar patterns of failure vs. non-BAC
NSCLC. Increased risk of distant metastases in this
series is likely confounded by interpretation of new BAC
versus true pulmonary metastases as implied by the
similar rates of extrapulmonary failure. Patients with
BAC should be considered for enrollment on ongoing
and future prospective studies of SBRT.
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